Saturday 17 October 2026
Export ZYBT’s income statement to Excel — free account
Zhengye Biotechnology Holding Limited
ZYBT Healthcare Drug Manufacturers Specialty & Generic
Zhengye Biotechnology Holding Limited’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, down 34.8% from fiscal 2024.
1.43
0.07
−4.67%
Follow ZYBT
| Older periods | Jun '24 | Dec '24 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
Current Ratio |
+1 more quarter Free account |
1.38 | 1.31 | 1.49 | 1.14 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
17.92% | 17.52% | 17.00% | 17.10% | |
Debt/Equity |
0.25 | 0.25 | 0.23 | 0.24 | |
Asset Turnover |
— | — | — | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(1.40) | (0.56) | (0.05) | (0.04) | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.13 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(0.16) | 3.78 | (2.04) | 1.77 | |
Working Capital |
7.20 | 5.71 | 9.30 | 2.42 | |
Capital Expenditures |
(2.18) | (1.85) | (0.09) | (0.14) | |
Net Current Asset Value |
7.14 | 5.05 | 8.64 | 1.09 | |
| Other line items | |||||
Quick Ratio |
0.67 | 0.69 | 0.72 | 0.60 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
— | — | — | 6.93 | |
Average Payables |
— | — | — | 6.29 | |
Average Inventory |
— | — | — | 6.81 | |
Average Assets |
— | — | — | 65.60 | |
Average Common Equity |
— | — | — | 45.27 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates